Kaye Scholer

From Wikipedia, the free encyclopedia
  (Redirected from Kaye Scholer LLP)
Jump to: navigation, search
Kaye Scholer
Kaye Scholer
Headquarters 425 Park Avenue
New York City
No. of offices 9
No. of attorneys 450+
Major practice areas General practice
Revenue N/A
Date founded 1917 (New York City)
Company type LLP
Website
www.kayescholer.com

Kaye Scholer is a law firm founded in 1917 by Benjamin Kaye and Jacob Scholer. The firm has more than 450 attorneys in nine offices located in the cities of Chicago, Frankfurt, London, Los Angeles, New York (headquarters), Shanghai, Palo Alto, Washington, D.C., and West Palm Beach.

Contents

Reputation and Recognition[edit]

Kaye Scholer is internationally known for being a leading litigation firm. Its particular areas of litigation strength include antitrust, intellectual property, and products liability. In 2008, Kaye Scholer was named Product Liability Firm of the Year by Chambers and Partners. In 2005, 2006 and 2007, The National Law Journal named Kaye Scholer to its list of top 10 elite litigation defense firms, making Kaye Scholer the only law firm to appear on this list for the three years it had run. In 2006, The American Lawyer magazine selected Kaye Scholer as the products liability litigation firm of the year. [1]

Kaye Scholer also has a well-developed transactional practice, including world-class expertise [2] in aviation, bankruptcy, finance, mergers and acquisitions, private equity, and real estate.

In the life sciences arena, Kaye Scholer was recognized in 2010 as “one of the most well regarded firms” for life sciences by The International Who’s Who of Life Sciences Lawyers 2010. Leora Ben-Ami and Steven Glickstein were recognized as two of the 12 “Most Highly Regarded Individuals” in the world — Kaye Scholer was the only law firm with more than one lawyer ranked in this exclusive category. On September 10, 2009, at an awards ceremony in Basel, Switzerland, capping Novartis AG's Global Legal Meeting, Kaye Scholer received the company's first-ever Preferred Provider Award for Excellence.[3]

Kaye Scholer is one of the nation's most profitable large law firms, according to American Lawyer magazine. Kaye Scholer maintains a reputation[citation needed] for being a collegial firm, something of a rarity in law firms of its size and economic success.

History[edit]

Founded as in 1917 in New York by Benjamin Kaye and Jacob Scholer. Scholer was a graduate of New York Law School. Kaye was a banking lawyer and noted playwright. His work includes She Couldn't Say No, which premiered on Broadway in 1926 and was adapted for the screen in 1930 and 1940.[4] The firm was known as Kaye, Scholer, Fierman, Hays and Handler for many years.

Kaye Scholer launched an office in Washington, D.C. in 1980 that now employs 50 attorneys.

Charges brought by the Office of Thrift Supervision against the firm in 1992 related to its representation of Charles Keating and his bank, Lincoln Savings and Loan, generated one of the most prominent legal ethics controversies of the decade.[5]

Kaye Scholer opened an office in West Palm Beach in 1997 where it focuses on real estate and estate planning law.

Former US Senator Abraham Ribicoff joined Kaye Scholer as Senior Counsel in 1981. Ribicoff had previously sponsored the bill that opened up trade between the US and China. As a result of his influence, Kaye Scholer was able to further expand into the Asian market, becoming the first New York-based firm to open a Shanghai office in 1998.[6] [7]

Kaye Scholer opened offices in London and Chicago in 2001; the firm's Frankfurt office opened soon after in 2002. In 2010, the firm opened its ninth office in Palo Alto, offering a full range of legal services to technology companies and private investment firms in Silicon Valley. From complex intellectual property matters involving patents, copyrights, trademarks and trade secret disputes for the software, hardware, computer, electronics, entertainment and movie industries to private and public financings, joint ventures, licensing, acquisitions and fund formations, Kaye Scholer successfully delivers sophisticated, focused and efficient representation to companies throughout Silicon Valley and Northern California.[8]

Following the merger of London-based Clifford Chance and legacy firm Rogers & Wells, Kaye Scholer benefited from a series of key lateral partners in intellectual property and bankruptcy.[9][10]

Notable Mandates[edit]

Transactional

  • Represented Meggitt-USA in its sale of one of its subsidiaries, formerly known as Keith Products, to Air Comm Corporation (ACC).
  • Represented Novartis on the purchase, by generics division Sandoz, of specialty dermatology generics company Fougera Pharmaceuticals for $1.525 billion in an all cash transaction.[11]
  • Assisted longtime client Onex Corp. in its $2.3 billion acquisition of USI Insurance Services LLC from a private fund managed by Goldman Sachs Group Inc.
  • Advised The Cooper Spirits Company, maker of artisanal elderflower liqueur St-Germain, in that product’s acquisition by the world’s largest privately held spirits company, Bacardi.
  • Helped GlaxoSmithKline Vaccines structure and negotiate its complex public-private collaborative partnership arrangements with The Texas A&M University System, Kalon Biotherapeutics and the US Department of Health and Human Services/Biomedical Advanced Research and Development Authority for the development and manufacture of vaccines to protect against pandemic and seasonal influenza.
  • Represented Bank of America, N.A., as administrative agent, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners, in an unsecured revolving credit facility of $2.5 billion and an unsecured term loan facility of $750 million for ERP Operating Limited Partnership, the multifamily residential property business of Equity Residential.
  • Advised private equity fund Moelis Capital Partners, as owners of portfolio company Dr. Fresh LLC, in the acquisition of REACH® brand toothbrushes from the Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
  • Represented Wind Point Partners in multiple acquisitions of consumer products companies, including certain assets of Consolidated Biscuit Company, and on the same day, the Cereal Division of Golden Temple of Oregon, LLC, a leading manufacturer and marketer of all-natural ready-to-eat cereals, bulk granola and granola snacks.
  • Advised Essie Cosmetics in its agreement to be acquired by L'Oréal USA.
  • Represented Sandoz in its agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company.
  • Advised Jarden Corporation, a leading provider of niche consumer products used in and around the home, in multiple acquisitions, including its acquisition of the Mapa Spontex baby care and home care businesses of French conglomerate Total S.A.
  • Represented ASP Westward, a portfolio company of American Securities, and publisher of 60 weekly and daily newspapers, in its acquisition of two East-Texas newspapers from Cox Enterprises Inc.
  • Represented Parsons Brinckerhoff Inc. in connection with the merger agreement with Balfour Beatty plc.
  • Represented the nine-person special committee of Harrah’s board of directors in the $27.8B sale of Harrah’s Entertainment Inc. to private equity firms TPG and Apollo Management in 2008.
  • Advised WCI Steel along with Boston law firm McDermott Will & Emery in its acquisition by OAO Severstal in 2008, a transaction valued at $327 million.
  • Represented Onex Corporation in its acquisition of the Health Group of Eastman Kodak Company for cash consideration of $2.35 billion in 2007.
  • Counseled Onex Corporation in its acquisition of the Wichita/Tulsa division of Boeing Commercial Airplanes for consideration of $.9 billion in cash in 2005.
  • Previously represented Onex Corporation and Oaktree Capital Management in their C$2 billion disposal of Loews Cineplex Entertainment Corporation to Bain Capital in 2004.
  • Advised Chef America Inc. in its acquisition by Nestle SA for total consideration of $2.6 billion in cash and debt. The deal closed in October 2002.
  • Advised RCA in the formation of a joint venture with Bertelsmann called RCA/Ariola International in 1985.
  • Represented the New York Yankees when George Steinbrenner purchased the team from CBS in 1973.

Litigation

  • As National Counsel to Knauf Plasterboard Tianjin (KPT), developed, negotiated and secured approval for a landmark global class action settlement and negotiated the settlement for In re: Chinese-Manufactured Drywall Products Liability Litigation.
  • Persuaded the Trademark Trial and Appeal Board (TTAB) to reverse the US Patent and Trademark Office’s refusal to give The Hershey Company a trademark registration for the design of its iconic chocolate bar
  • Represented the former Chairman and CEO of IT management solutions company CA, Inc. in a series of securities class action and derivative cases
  • Achieved a victory for clients Vintage Pharmaceuticals and Endo Pharmaceuticals Holdings in a 2012 case involving allegedly improperly packaged birth control pills by securing a denial of a plaintiff’s motion for class certification and a partial grant of summary judgment.[12]
  • Won a California federal court order on behalf of Complete Genomics, which granted a summary judgment invalidating all nine of Illumina's claims to a patent covering a DNA sequencing method that Complete Genomics was accused of infringing. [13]
  • Obtained summary judgment for 15 of the leading brand name prescription drug manufacturers and PhRMA, their trade association, in Clayworth, et al. v. Pfizer Inc, et al., dismissing on the merits an action by California retail pharmacies alleging a conspiracy among brand name prescription drug manufacturers to fix prices in violation of the Cartwright Act, California’s state antitrust law.[14]
  • Helped its clients OSI Pharmaceuticals, Inc., Pfizer, Inc. and Genentech, Inc. successfully defeat a challenge by generic drug manufacturer, Mylan Pharmaceuticals, Inc. (Mylan), which was seeking FDA approval to market a generic version of Tarceva®.[15]
  • Represented 4Kids Entertainment, Inc., an entertainment and media company that has managed the US licensing, broadcast and merchandising rights to many popular Japanese animated shows including Yu-Gi-Oh!, in the company’s Chapter 11 bankruptcy. This reorganization plan was named one of the Most Successful Restructurings of 2012 by Turnarounds & Workouts.
  • Represented Wyeth in a landmark victory - Wyeth v. Kappos in January 2010, successfully challenging, at the district court level and on appeal, the U.S. Patent and Trademark Office’s interpretation of the statute designed to compensate patent holders for loss of patent term due to delays in processing applications.
  • Successful defense of Pfizer in Viagra product liability litigation over the past decade; obtaining a long line of summary judgment decisions against claims of various diseases and ailments.
  • Lead patent counsel for Pfizer in its patent infringement lawsuit against Teva Pharmaceuticals U.S.A., Inc. in which Teva attempted to bring a generic version of Celebrex to market.
  • Previously represented PepsiCo in various litigation matters during the ongoing Cola Wars with The Coca-Cola Company
  • Successfully represented Xerox Corporation in the longest federal civil jury trial up to that time in 1977, in which plaintiff SCM alleged that Xerox abused its patent portfolio to create a monopoly of the plain paper copy industry.

Noted Alumni[edit]

Among Kaye Scholer's alumni are former Senator Abraham Ribicoff; Kenneth Feinberg, Special Master of the U.S. Government's September 11th Victim Compensation Fund; and Milton Handler, an antitrust expert who drafted some of the nation's most notable laws on that subject.[16]

References[edit]

  1. ^ Press, Aric. [Litigation Department of the Year "Litigation Department of the Year"] Check |url= scheme (help). Retrieved 6 March 2013. 
  2. ^ "Chambers USA 2012: Kaye Scholer LLP". Chambers and Partners. 
  3. ^ "Kaye Scholer Chosen for Novartis's Inaugural Preferred Provider Award for Excellence". Retrieved 6 March 2013. 
  4. ^ "Filmography by type for Benjamin M. Kaye". 
  5. ^ William H. Simon, "The Kaye Scholer Affair: The Lawyer's Duty of Candor and the Bar's Temptations of Evasion and Apology" (2006) http://onlinelibrary.wiley.com/doi/10.1111/j.1747-4469.1998.tb00705.x/abstract
  6. ^ "Chambers Asia 2012 - Kaye Scholer LLP". 
  7. ^ The Lawyer, 'NYC firm first to Shanghai,' (1998) http://www.thelawyer.com/cgi-bin/item.cgi?id=95588
  8. ^ Lee, Kevin. "Former Kaye Scholer Leader Heads to Greenberg Traurig". The Daily Journal. 
  9. ^ The Lawyer, 'Clifford Chance New York rainmaker quits for Kaye' (2003) http://www.thelawyer.com/cgi-bin/item.cgi?id=107812
  10. ^ The Lawyer, 'CC hit for six by Kaye Scholer NY raid' (2005) http://www.thelawyer.com/cgi-bin/item.cgi?id=114093
  11. ^ Wilson, Daniel. "FTC OKs Novartis' $1.5B Fougera Buy With Divestitures". Law360. 
  12. ^ Bolado, Carolina. "Qualitest Beats Class Cert. Bid In Birth Control Recall Suit". Law360. 
  13. ^ Randles, Jonathan. "Illumina Patent Claims Invalidated In DNA Sequencing Row". Law360. 
  14. ^ Li, Victor. "1st District Rules in Favor of Big Pharma in Antitrust Suit". The Recorder. 
  15. ^ Li, Victor. "Kaye Scholer Fends Off Challenge to Pfizer Cancer Drug Patents". The American Lawyer. 
  16. ^ Nasar, Sylvia. "Milton Handler, 95, Is Dead; Antitrust Expert Wrote Laws". The New York Times. 

External links[edit]